Jove
Visualize
Contact Us

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

8.9K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.9K
Abnormal Proliferation02:23

Abnormal Proliferation

4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Immunoglobulin-like Cell Adhesion Molecules01:31

Immunoglobulin-like Cell Adhesion Molecules

3.3K
Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
3.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

530
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
530
Immunocytochemistry and Immunohistochemistry01:22

Immunocytochemistry and Immunohistochemistry

11.4K
Immunocytochemistry (ICC) and immunohistochemistry (IHC) are techniques that use antibodies to check for specific proteins or antigens in a sample. The technique was first published by Albert Coons in 1941 to detect the presence of pneumococcal antigen in tissue sections from mice infected with Pneumococcus. Immunocytochemistry helps localization of proteins or antigens in individual cells like blood cells, stem cells, etc., while immunohistochemistry does the same for tissue samples.
These...
11.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Brain Network Connectivity Predicts Survival in Diffuse Midline Glioma.

Cancer discovery·2026
Same journal

First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts.

Cancer discovery·2026
Same journal

CDK8 Inhibition Releases the Muscle Differentiation Block in Fusion-driven Alveolar Rhabdomyosarcoma.

Cancer discovery·2026
Same journal

CDK8 inhibition induces Mediator trapping and impairment of the EWSR1::FLI1 transcriptional program in Ewing sarcoma.

Cancer discovery·2026
Same journal

SEZ6-Targeted ADC Shows Preliminary Efficacy in Small Cell Lung Cancer.

Cancer discovery·2026
Same journal

Nonprofit Acquires Abandoned Leukemia Drug Supply.

Cancer discovery·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 11, 2025

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
11:10

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

14.1K

Intracellular Oncoproteins Can Be Targeted by Mutation-Specific Dimeric IgA

    Cancer Discovery
    |November 17, 2023
    PubMed
    Summary

    Engineered dimeric IgA (dIgA) antibodies effectively target mutated oncodrivers within cancer cells, significantly inhibiting tumor growth. This novel immunotherapy approach shows promise for cancer treatment.

    Area of Science:

    • Immunology
    • Oncology
    • Biotechnology

    Background:

    • Cytoplasmic oncodrivers are key targets in cancer therapy.
    • Dimeric IgA (dIgA) offers unique therapeutic potential due to its structure and effector functions.
    • Engineering dIgA for specific intracellular targeting remains a challenge.

    Purpose of the Study:

    • To engineer dIgA antibodies capable of targeting mutated cytoplasmic oncodrivers.
    • To evaluate the efficacy of engineered dIgA in abrogating tumor growth.

    Main Methods:

    • Development of dIgA constructs with specificity for intracellular oncodriver mutations.
    • In vitro and in vivo models to assess dIgA delivery and anti-tumor activity.
    • Analysis of tumor growth inhibition and potential mechanisms of action.

    More Related Videos

    Assessing Somatic Hypermutation in Ramos B Cells after Overexpression or Knockdown of Specific Genes
    08:12

    Assessing Somatic Hypermutation in Ramos B Cells after Overexpression or Knockdown of Specific Genes

    Published on: November 1, 2011

    20.0K
    Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
    09:53

    Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

    Published on: February 6, 2017

    11.5K

    Related Experiment Videos

    Last Updated: Jul 11, 2025

    Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
    11:10

    Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

    Published on: June 29, 2016

    14.1K
    Assessing Somatic Hypermutation in Ramos B Cells after Overexpression or Knockdown of Specific Genes
    08:12

    Assessing Somatic Hypermutation in Ramos B Cells after Overexpression or Knockdown of Specific Genes

    Published on: November 1, 2011

    20.0K
    Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
    09:53

    Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

    Published on: February 6, 2017

    11.5K

    Main Results:

    • Engineered dIgA successfully targeted mutated cytoplasmic oncodrivers.
    • Significant abrogation of tumor growth was observed in treated models.
    • Demonstrated the potential for intracellular antibody-based cancer therapy.

    Conclusions:

    • Engineered dIgA represents a promising strategy for targeting intracellular oncogenic drivers.
    • This approach offers a novel therapeutic avenue for cancers driven by specific mutations.
    • Further development could lead to new treatments for various malignancies.